Blog
RSS FeedPosted by Michael Wonder on 12 Dec 2025
Landmark UK-US pharmaceuticals deal to safeguard medicines access and drive vital investment for UK patients and businesses
1 December 2025 - Tens of thousands of NHS patients will benefit from a landmark trade deal between the UK and the ...
Posted by Michael Wonder on 03 Dec 2025
To avoid tariffs, UK agrees to Trump’s demand to pay more for drugs
3 December 2025 - President Trump has complained that wealthy countries like Britain pay too little for drugs, leading America to ...
Posted by Michael Wonder on 26 Nov 2025
UK set to raise prices of drugs in US agreement
23 November 2025 - The UK Government is in the late stages of agreeing a major drug pricing deal with ...
Posted by Michael Wonder on 03 Oct 2025
Bristol Myers Squibb plans to launch Cobenfy (xanomeline and trospium chloride) in the UK at a list price equal to the US launch price
22 September 2025 - Bristol Myers Squibb plans to launch Cobenfy (xanomeline and trospium chloride), in the UK in 2026. ...
Posted by Michael Wonder on 29 Sep 2025
AbbVie announces UK pricing strategy for Elahere (mirvetuximab soravtansine-gynx)
29 September 2025 - The list price will be consistent with the US to reflect the value of the innovation. ...
Posted by Michael Wonder on 29 Aug 2025
UK Government, pharma industry fail to agree on medicines payment scheme
28 August 2025 - Negotiations between the UK Government and the pharmaceutical industry have ended without an agreement on changes ...
Posted by Michael Wonder on 14 Jan 2025
Design and features of pricing and payment schemes for health technologies: a scoping review and a proposal for a flexible need driven classification
13 January 2025 - In a context of growing clinical and financial uncertainty, pricing and payment schemes can act as possible ...
Posted by Michael Wonder on 24 Oct 2024
Driving down the cost of biologics: lessons from a nationalised health care system
18 October 2024 - Few treatments have revolutionised care for people with chronic inflammatory disorders more than biologic and small molecule ...
Posted by Michael Wonder on 05 Dec 2023
Government sends mixed message to global life science investors
5 December 2023 - The Government has published new terms for the Statutory Scheme for branded medicines, maintaining sales rebates ...
Posted by Michael Wonder on 20 Nov 2023
Landmark medicines deal to boost nation’s health, save NHS £14 billion, and support research investment
20 November 2023 - Pro-innovation and pro-competition agreement will introduce a new mechanism to support lower industry payment rates for more ...
Posted by Michael Wonder on 12 Oct 2023
Life sciences leaders unite to condemn radical plans to rewrite medicines scheme
9 October 2023 - Over twenty industry leaders from companies supplying the NHS with essential medicines warn that radical plans to ...
Posted by Michael Wonder on 20 Jul 2023
New Government consultation on medicine clawbacks will harm investment, says ABPI
19 July 2023 - In a move that will further damage UK life sciences investment, the Government has launched a ...
Posted by Michael Wonder on 14 May 2023
Negotiations begin for a new medicine pricing scheme
4 May 2023 - Negotiations for a new voluntary scheme for branded medicines pricing to open between the government, NHS ...
Posted by Michael Wonder on 29 Apr 2023
Prioritising patients in negotiations over drug pricing
14 April 2023 - Overpaying for medicines diverts funds away from other treatments and services. ...
Posted by Michael Wonder on 03 Mar 2023
ABPI response to Government Statutory Scheme rise
2 March 2023 - The Government has confirmed plans to raise the revenue clawback rate paid by pharmaceutical firms subject ...